Background Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte
antigen 4 to enhance antitumour immunity. Our aim was to assess the use of ipilimumab …

B7-H1 participates in T-cell costimulation functioning as a negative regulator of immunity.
Recent observations suggest that B7-H1 is expressed by renal cell carcinoma (RCC) tumor …

Expression of B7-H1, a costimulating glycoprotein in the B7 family, is normally restricted to
macrophage-lineage cells, providing a potential costimulatory signal source for regulation of …

Defective dendritic cell (DC) function has been described previously in cancer patients and
tumor-bearing mice. It can be an important factor in the escape of tumors from immune …

BACKGROUND The objective of the current study was to develop an algorithm to predict
progression to metastases after radical nephrectomy for patients with clinically localized renal …

Purpose : We reviewed our surgical experience with small renal tumors, comparing overall
survival in patients treated with radical and partial nephrectomy. Materials and Methods : …

Purpose: B7-H1 is expressed by clinically aggressive forms of renal cell carcinoma (RCC)
and predicts adverse outcome. B7-H1 is known to impair host immunity via interaction with the …

Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte
antigen 4. We evaluated treatment with ipilimumab in asymptomatic or minimally …

… Eugene Kwon has filed a patent application pertaining to B7-H1 as a prognostic marker in
… Eugene Kwon has filed a patent application pertaining to B7-H1 as a prognostic marker in …

To develop a syngeneic transplantable system to study immunotherapeutic approaches for
the treatment of prostate cancer, three cell lines were established from a heterogeneous 32 …